Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naltrexone,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : National Institute on Drug Abuse
Deal Size : $11.0 million
Deal Type : Funding
BioCorRx Awarded $11M NIDA Grant for BICX104 Naltrexone Implant for MUD Treatment
Details : BioCorRx will focus funding on clinical development of BICX104 (naltrexone) in combination with Bupropion, currently in preclinical studies for methamphetamine use disorder.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 28, 2024
Lead Product(s) : Naltrexone,Bupropion Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : National Institute on Drug Abuse
Deal Size : $11.0 million
Deal Type : Funding
Lead Product(s) : Naltrexone,Magnesium Stearate API
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Lead Product(s) : Naltrexone,Magnesium Stearate API
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 18, 2023
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BICX104, implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection for the treatment of opioid use disorder (OUD).
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2022
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BICX104 is an eroding subcutaneous implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $9.3 million
Deal Type : Funding
Details : BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002. Part of this supplemental grant will be used to develop and refine systems and strategies ...
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 11, 2022
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $9.3 million
Deal Type : Funding
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The BICX104 clinical study in two parallel groups of 12 randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injectio...
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant
Details : BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD). The company submitted the IND to the FDA last month. The first-in-human clinical trial.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 07, 2021
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed under BioCorRx Pharmaceuticals, Inc., BioCorRx’s controlled R&D subsidiary.
Brand Name : BICX104
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 08, 2021
Lead Product(s) : Naltrexone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : Societal CDMO
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?